Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2408871 | Vaccine | 2007 | 10 Pages |
Abstract
A bigenic MUC1.Tg/MIN mouse model was developed by crossing Apc/MIN/+ (MIN) mice with human MUC1 transgenic mice to evaluate MUC1 antigen-specific immunotherapy of intestinal adenomas. The MUC1.Tg/MIN mice developed adenomas at a rate comparable to that of MIN mice and had similar levels of serum MUC1 antigen. A MUC1-based vaccine consisting of MHC class I-restricted MUC1 peptides, a MHC class II-restricted pan-helper peptide, unmethylated CpG oligodeoxynucleotide and GM-CSF caused flattening of adenomas and significantly reduced the number of large adenomas. Immunization was successful in generating a MUC1-directed immune response evidenced by increased MUC1 peptide-specific anti-tumor cytotoxicity and IFN-γ secretion by lymphocytes.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Emmanuel T. Akporiaye, Deborah Bradley-Dunlop, Sandra J. Gendler, Pinku Mukherjee, Cathy S. Madsen, Tobias Hahn, David G. Besselsen, Sharon M. Dial, Haiyan Cui, Katrina Trevor,